Navigation Links
Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share
Date:12/10/2010

reviously announced tender offer for $4.25 per share until 12:00 Midnight, New York City time, on December 17, 2010, unless the offer is further extended.  The tender offer was previously scheduled to expire at 12:00 Midnight, New York City time, on December 10, 2010.  All other material terms and conditions of the tender offer remain unchanged.

Previously, on September 15, 2010, Ramius announced that it commenced a tender offer to acquire all of the outstanding shares of common stock of Cypress for $4.25 per share in cash. That offer represented a 70% premium over the $2.50 closing price of Cypress' stock on July 16, 2010, the last trading day before Ramius publicly announced its proposal to acquire the Company for $4.00 per share in cash.  

As of the close of business on December 9, 2010, approximately 2,993,774 shares of Common Stock of Cypress, representing approximately 7.8% of all outstanding shares, were validly tendered and not withdrawn pursuant to the tender offer.  This amount does not include the 3,815,000 shares owned by Ramius and its affiliates.

Ramius has also entered into a confidentiality agreement with Cypress to conduct due diligence in connection with its tender offer or a possible negotiated transaction with Cypress.  The confidentiality agreement does not restrict Ramius' ability to continue or consummate its current tender offer or to conduct a proxy solicitation in connection with the Company's 2011 Annual Meeting of Stockholders.

The full text of the letter follows:

Dear Board Members:

Following our conversations with Perella Weinberg Partners over the past few weeks, this letter sets forth the willingness of Ramius V&O Acquisition LLC and its affiliates ("V&O Acquisition") to offer to acquire all of the outstanding common stock (the "Common Stock") of Cypress Bioscience, Inc. ("Cypress") not already owned by V&O Acquisition and its affiliates in a negotiated tra
'/>"/>

SOURCE Ramius LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cypress Denies Ramius Legal Right to Stockholder List Materials
2. UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America
3. U of C scientist offers better ways to engineer Earths climate to prevent dangerous global warming
4. Emerson Ecologics Exclusively Offers EcoNugenics ProstaCaid
5. New paper offers breakthrough on blinking molecules phenomenon
6. Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome
7. Research from Rensselaer Polytechnic Institute professor offers clues to Alzheimers disease
8. Carl Zeiss Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging
9. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
10. Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists
11. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... the University of Illinois helped lead a collaborative ... for serious Staphylococcus aureus (Staph) infections. The research, ... of Science magazine, comes at a time when ... methicillin-resistant S. aureus) are spreading in epidemic proportions ...
... Pipeline ... Continues to Mature, SOUTH SAN FRANCISCO, Calif., Feb. 14 ... full,year and fourth quarter ended December 31, 2007., Revenues for the ... revenues for the full year was primarily due to,revenue recognition associated with ...
... IRVINE, Calif., Feb. 14 SectorWatch.biz announces the,availability ... the news and,driving markets today., Investors can ... by,visiting: http://www.SectorWatch.biz -- Click on MarketStats, ... include:,CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), ...
Cached Biology Technology:New approach may render disease-causing staph harmless 2New approach may render disease-causing staph harmless 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... with research associate Jerilyn Walker and assistant professor Miriam Konkel, ... ancient jumping genes called Alu, which are more than 16 ... the Zoological Society of San Diego and the Institute of ... open access journal Mobile DNA . These tiny ...
... are being investigated as a way of improving drug response ... launched today (Monday). Scientists at the Cancer Research UK ... (ECMC) in Leicester will investigate whether tablets containing curcumin ... to the standard treatment for bowel cancer that has spread. ...
... is available in German . Halle/Saale. In ... special strategies. These differ in part considerably from the propagation ... Dr. Sonja Knapp of the Helmholtz Centre for Environmental Research ... current issue of the scientific journal Ecology Letters . ...
Cached Biology News:LSU research finds orangutans host ancient jumping genes 2Trial launched into curry chemical's cancer-fighting properties 2Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Cytokeratin TYPE II Reacts with most ... epidermal cell keratin of 86 and 58kD ... Broad keratin reactivity is found on human ... Immunogen: Human epidermal cells ...
Biology Products: